Syntiron LLC, is dedicated to developing innovative vaccines for humans. Our patented microbial antigen discovery and purification technology targets proteins that acquire iron, a critical nutrient that is required for survival of the bacteria. These proteins are expressed on the cell surface and are similar among different strains, making them ideal vaccine antigens. Our proprietary platform enables rapid identification of these proteins, which can then be directly extracted from the host cell or produced recombinantly for preclinical vaccine development.
There is no investment information
No recent news or press coverage available for Syntiron.
We care about your data, and we'd love to use cookies make your experience better.
